A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-022 Following Single and Multiple Escalating Dose
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2018
At a glance
- Drugs ICP 022 (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; First in man
- Sponsors Innocare Pharma Australia
- 06 Jun 2018 According to an InnoCare Pharma media release, status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Planned End Date changed from 24 Oct 2017 to 30 Apr 2018.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.